BLOG

How NK Cells Differ From Other Immune Cells and Why It Matters

7 min read

Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.

If you are researching cancer immune cell therapy, you will quickly meet a long list of immune cell names: T cells, B cells, dendritic cells, and natural killer (NK) cells. They are often mentioned together, yet they do very different jobs. Understanding where NK cells fit can help you ask better questions before you consider NK cell therapy in Japan.

This article explains, in plain language, how NK cells differ from other immune cells, what that means for the way NK cell therapy is designed, and what international patients should confirm with a doctor at Grand Green Osaka Umekita Clinic in Osaka. It is general information, not medical advice, and it cannot replace an individual consultation.

The short answer: NK cells act as first responders

NK cells are a type of lymphocyte that circulates in the blood. Their defining feature is that they can detect and attack abnormal cells, such as cancer cells and virus-infected cells, without waiting for instructions from other immune cells. This is why they are described as part of the innate immune system, the body’s built-in first line of defense.

Other immune cells tend to work in a more coordinated, step-by-step way. Some cells need to be shown a specific target before they respond, and others support or direct the response rather than attacking directly. Neither approach is simply better; they complement each other. NK cell therapy focuses on the first-responder role, with the aim of strengthening one part of the immune system rather than replacing the whole of it.

How NK cells work compared with other immune cells

Even in healthy people, abnormal cells that could develop into cancer are thought to arise every day. Immune surveillance is thought to be one reason most people do not develop cancer: immune cells, including NK cells, are believed to find and remove many of these cells. This mechanism is known as immune surveillance. NK cells patrol the body and can act on abnormal cells they encounter, using molecules such as perforin to attack directly.

Other parts of the immune system contribute differently. Some cells specialize in remembering a particular threat so that the response is faster next time. Others produce signals that organize the overall response. Because these roles overlap, researchers study how the different cell types interact, and no single cell type should be viewed as the whole story of how the body responds to cancer.

It is also important to be realistic. NK cell activity has been reported to decline with age, with stress, and with the effects of cancer itself. Research on NK cells is ongoing, and results from laboratory or early studies should not be read as proof that a treatment will work for any individual person.

Why this difference matters for NK cell therapy

The idea behind NK cell therapy is to work with your own immunity. At Grand Green Osaka Umekita Clinic, NK cells obtained from a standard blood draw are activated and expanded at a specialized, licensed cell processing facility. The cells are then returned to your body by intravenous infusion. By returning NK cells that are greater in number and higher in activity, the therapy aims to reinforce immune function that may have weakened.

Because the cells come from your own body (autologous cells), the risk of rejection is considered low, and serious side effects have rarely been reported. However, temporary reactions such as fever or fatigue may occur, and individual responses differ. Treatment involves a blood draw and an infusion, without hospitalization, so many people can continue daily life during treatment. Your doctor will explain what to expect in your specific situation.

A responsible discussion also includes limits. NK cell therapy is not a replacement for standard cancer treatment, and it cannot be promised to produce any particular outcome. The expected benefit, if any, depends on the individual and should be discussed openly with a physician.

How NK cell therapy relates to standard cancer treatment

NK cell therapy is generally not intended to compete with surgery, chemotherapy, or radiation therapy. It is generally considered unlikely to interfere with these options, so it may be considered alongside them if your doctors agree. Some patients also consider it after treatment ends, with the aim of supporting immune function or helping to lower the risk of recurrence, although the expected effect should be discussed carefully with a doctor.

If you are already receiving standard treatment, your oncology team remains central to your care. The clinic can coordinate with the medical institution providing your standard treatment, and sharing your records and treatment plan helps your doctors make decisions together. Please do not stop or change any current treatment without speaking to the physician who prescribed it.

Rules, costs, and what to confirm in Osaka

In Japan, NK cell therapy is provided as a self-pay (non-insured) treatment, which means it is not covered by national health insurance. It is delivered under the Act on the Safety of Regenerative Medicine, through a regenerative medicine provision plan submitted to and accepted by the authorities. Fees, treatment schedule, risks, side effects, and whether the therapy suits your condition must all be confirmed during a consultation with a doctor.

Before you decide, it helps to prepare a short list of questions, for example:

  • How does NK cell therapy differ from other immune cell therapies I have read about?
  • What is known and not known about its effect for my type and stage of cancer?
  • What temporary reactions could occur, and when should I contact the clinic?
  • How would the therapy fit with my current or planned standard treatment?
  • What are the total fees, the number of visits, and the timeline if I travel from overseas?

Next steps for international patients

Grand Green Osaka Umekita Clinic is located in the Umeda area of Osaka and offers an information page for international patients, so you can review the overview in English before you reach out. A consultation is the right place to talk through your medical history, your goals, and whether NK cell therapy is a reasonable option to consider alongside your existing care.

If you are comparing options, take your time. Ask for explanations in a language you are comfortable with, bring your latest medical records, and discuss the plan with your home physician as well. A well-informed decision is more valuable than a quick one.

Learn more about NK Cell Therapy

References

Supervising Physician

Hidenori Shimada

Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic

Hidenori Shimada

Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.

* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.

Back to article list › Back to NK Cell Therapy ›

Grand Green Osaka South Building, Gate Tower 5F 5-54 Ofuka-cho, Kita-ku, Osaka 530-0011, Japan

TEL: 06-7653-8493 FAX: 06-7635-8052

Contact